7-AMINOCEPHALOSPORANIC ACID DERIVATIVE AS INHIBITOR OF IL-15 AND IL-2 ACTIVITY
The invention relates to 7-zminocephalosporanic acid derivative, Cefazolin, for use as the inhibitor of IL-15 and IL-2 receptors in the prevention and treatment of IL-15 and IL-2 overproduction related diseases.
1 . 7-Aminocephalosporanic acid derivative—Cefazolin, for use as the inhibitor of IL-15 and IL-2 receptors in the prevention and treatment of IL-15 and IL-2 overproduction related diseases.
2 . Cefazolin for use according to claim 1 , wherein the disease is rheumatoid arthritis, psoriasis, inflammatory bowel disease, sarcoidosis, T-cell leukemias or transplant rejection.
3 . Cefazolin for use according to claim 1 , wherein the disease is rheumatoid arthritis.
4 . Cefazolin for use according to claim 1 , wherein Cefazolin is to be administered in a therapeutically effective dose to an individual in need of such a treatment.
5 . Cefazolin for use according to claim 4 , wherein Cefazolin is to be administered as a single dosage form.
6 . Use of Cefazolin for manufacturing of the pharmaceutical formulation for the prevention and treatment of the diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, sarcoidosis, T-cell leukemias or transplant rejection.
7 . Pharmaceutical formulation comprising therapeutically effective amount of Cefazolin as the active ingredient and pharmaceutically acceptable carriers and/or excipients for use in the prevention and treatment of the diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, sarcoidosis, T-cell leukemias or transplant rejection.
8 . Pharmaceutical formulation according to claim 7 , in a form suitable for intra-venous or intra-muscular administration.